Simple Summary Targeted therapy has become essential in the treatment of non-small cell
lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer …

Background: advanced-stage non-small cell lung cancer (NSCLC) is characterized by
having limited treatment options and thus a poor prognosis. However, new treatment …

Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …

Objective The efficacy and safety of afatinib in elderly patients with EGFR-mutated non-small-
cell lung cancer (NSCLC) have not been evaluated. This study aimed to assess the efficacy …

Lung cancer (LC) is associated with ageing, with the average age of affected individuals
being approximately 70 years. However, despite a higher incidence and prevalence among …

Objectives Osimertinib is the primary treatment for patients with epidermal growth factor
receptor (EGFR) mutation-positive advanced non-small cell lung cancer. However, evidence …

Purpose: To develop and validate a prediction model for nonoperative EGFR-positive locally
advanced elderly esophageal cancer (LAEEC). Methods: Eighty EGFR-positive LAEEC …

Lung cancer is predominantly a disease of the elderly. This subgroup of patients poses
many challenges and an appropriate geriatric assessment is crucial for treatment …

Increasing insights into the hallmarks of cancer have reshaped the treatment landscape for
many solid tumors and have led to the availability of novel and highly effective targeted …

Lung cancer remains the leading cause of cancer-related deaths worldwide, with most
patients diagnosed at an advanced age. The treatment of non-small cell lung cancer …